



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231,
ON September 14, 2001

Audrey Boyd
September 14, 2001
DATE

Attorney Docket No.: B45082D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rentier, et al.
Serial No.: 09/865,637
Filed: May 25, 2001
For: Vaccines Against Varicella Zoster Virus Gene 63 Product

REQUEST FOR CORRECTED FILING RECEIPT

To Assistant Commissioner for Patents

Enclosed herewith is a copy of the Filing Receipt issued by the United States Patent and Trademark Office with changes noted thereon.


Applicants respectfully request that the United States Patent and Trademark Office correct the above-noted error and issue an amended Filing Receipt.

Please charge Deposit Account No. 19-2570 the sum of \$25.00 as required by 37 CFR 1.19(h) and charge any additional fees which may be required by this paper, or credit any overpayment, to said deposit account. A duplicate of this request is attached.

Respectfully submitted,

Zoltan Kerekes
Attorney for Applicants
Registration No. 38,938

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5024
Facsimile (610) 270-5090
N:\zk\apps\b45082d1\Req for Corrected Filing Receipt 2.doc

#6
cc
Receipt

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/865,637	05/25/2001	1638	710	B45082D1	4	9	3

CONFIRMATION NO. 4711

CORRECTED FILING RECEIPT



OC000000006535756

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939

Date Mailed: 09/10/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Bernard Rentier, Liege, BELGIUM;
Catherine Sadzot, Liege, BELGIUM;

Assignment For Published Patent Application

SmithKline Beecham Biologicals s.a.;
University of liege;

Domestic Priority data as claimed by applicant

2/4/97

THIS APPLICATION IS A DIV OF 09/117,711 ~~10/20/1998~~ ABN *
WHICH IS A 371 OF PCT/EP97/00520 02/04/1997
(*) Data inconsistent with PTO records.

Foreign Applications

UNITED KINGDOM 9602617.4 02/09/1996
UNITED KINGDOM 9626882.6 12/24/1996RECEIVED
SMITHKLINE BEECHAM
2001 SEP 12 A 11:23

If Required, Foreign Filing License Granted 07/03/2001

Projected Publication Date: 10/11/2001

Non-Publication Request: No

Early Publication Request: No

Title

Vaccines against varicella zoster virus gene 63 product

Preliminary Class

424

Data entry by : CARMICHAEL, SHIRELL

Team : 2600

Date: 09/10/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- o The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- o The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- o The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- o The docket number allows a maximum of 25 characters.
- o If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- o The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231